SCCS - Minutes of the Working Group Meeting on Cosmetic Ingredients of 5-6 October 2021



The Minutes of the Working Group Meeting on Cosmetic Ingredients includes the following items:

New mandates or information from DG GROW

(*) Opinion on Butylparaben

(*) Scientific advice for Homosalate used in face products (face cream and pump spray)

(*) Opinion on new hair dye Sodium Bromothymol Blue (C186)

(*) Potential mandate for revising the Opinion on TiO2

Draft Opinions discussed

(*) Kojic acid: the draft preliminary Opinion has been presented and will be further discussed at the plenary meeting.

(*) Genistein: the draft preliminary Opinion has been presented and will be further discussed at the plenary meeting.

(*) Daidzein: the draft preliminary Opinion has been presented and will be further discussed at the plenary meeting.

(*) Revision of the Vitamin A Opinion: the draft preliminary Opinion has been presented and will be further discussed at the plenary meeting.

(*) Aluminium (aggregate exposure): the draft preliminary Opinion has been presented and will be further discussed at the plenary meeting. A request for clarification to the Applicant is under preparation.

(*) 4-Methylbenzylidene camphor (4-MBC): the draft preliminary Opinion has been presented and will be further discussed at the plenary meeting.

(*) Scientific Advice (SA) on Triclocarban and Triclosan: the content of the file will be further discussed at the plenary meeting.

(*) Arbutins: the draft preliminary Opinion has been presented and will be further discussed at the plenary meeting

Comments on Opinions

(*) Preliminary Opinion on fragrance Methylsalicylate was published and open for comments until 8 September 2021. The Opinion and the SCCS responses to comments received will be finalised for adoption at plenary meeting (26-27 October).

(*) The WG discussed the follow-up of a question received on Lawsonia inermis (Henna) - SCCS/1511/13

The following preliminary opinions have been published for comment until 23 November 2021

(*) Butylated Hydroxytoluene (BHT)

(*)  Prostaglandin and analogues

CONTINUE READING ON ec.europa.eu

                   

Related News

Loading...